Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching Anti-TNF-alpha Agents in RA
NCT00796705Phase 4Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2008
- Primary completion
- Oct 2010
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Adalimumab with Etanercept (2 arms). Primary endpoints: Change in Disease Activity Score Using C-reactive Protein (DAS28[CRP]) in Non-Switchers Versus Switchers at Week 12 and Change in Disease Activity Score Using C-reactive Protein (DAS28[CRP]) at Week 12. Started Nov 2008; status: terminated.
02
Drugs
adalimumabetanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00796705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796705.